2Suppliers
0Customers
3Debt Items
0Related Chains

Context Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
BIOATLA-INC BIOATLA-INC 92% The Company agreed to pay BioAtla $4.5 million within five business days of the Amendment Date and an additional $2.0 million by August 1, 2026.
LINK-ASSIGNMENT-FOR-THE-BENEFIT-OF-CREDITORS-LLC LINK-ASSIGNMENT-FOR-THE-BENEFIT-OF-CREDITORS-LLC 90% we purchased all of the assets of Link associated with CT-95, including patent rights, know-how, regulatory filings, and inventory of drug substance and drug product

Context Therapeutics Inc. Customers

No clients on recordNo downstream customers found in our database for Context Therapeutics Inc..

Context Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CNTX-DEBT Debt stack $282,424 90% Market cache reports total debt of $282,424.
CNTX-DEBT-8758 Warrants outstanding: 345530 90% xbrl warrant detail from xbrl 2022-12-31.
CNTX-DEBT-8759 Xbrl Convertible 90% xbrl convertible detail from xbrl 2022-12-31.

Context Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Context Therapeutics Inc..

Context Therapeutics Inc. Ownership

HolderNameConfidenceEvidence
CNTX-OWNER-MPM-BIOIMPACT-LLC MPM BIOIMPACT LLC 90% 13F overlay lists MPM BIOIMPACT LLC as top holder; 61 tracked holders.

Context Therapeutics Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.